The latest on a closely-watched Amgen patent cases; how the White House is pitching drug pricing reforms

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by     STAT+: Solicitor general recommends Supreme Court shouldn't review an Amgen patent case By Ed Silverman Anna Moneymaker/Getty Images “The solicitor general explained this case was not a good vehicle for addressing the legal questions presented," said Nicholas Mitrokostas. Read More STAT+: White House pitches drug pricing reforms as a way to extend cancer patients' lives By Rachel Cohrs Anna Moneymaker/Getty Images The White House is pitching an added benefit to Democrats’ recent drug pricing reform package: lower cancer death rates. Read More 'Disaster to disaster': Underinvestment in public health systems obstructs response to Covid, monkeypox, Walensky says By Isabella Cueto Drew Angerer/Getty Images The CDC chief spoke to a bumpy response to monkeypox. As for Covid: "There are a lot of different ways to think about a pandemic being over." Read More Sponsor content by Optum Could clinicogenomics be the next big thing fueling R&D? Since the human genome was first sequenced, researchers have sought to use this information in ways that can improve individual and population health. But they soon realized that DNA sequence data alone has limited value when trying to understand the effects of genetic variation on human health. Clinicogenomics has provided them a path forward by linking genomic data to rich, longitudinal clinical information. Read this white paper to get an in-depth look into this rapidly evolving field of research. STAT+: Up and down the ladder: The latest comings and goings By Ed Silverman Alex Hogan/STAT From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. Read More Shakeup with Optum's health data licensing sparks an outcry among scientists By Casey Ross Adobe A move by Optum to change longstanding practices for licensing data to academic institutions has sparked an outcry among researchers. Read More Friday, September 23, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser